Topics:

Interim Results for MediGene's Oncolytic Virus NV1020

Interim Results for MediGene's Oncolytic Virus NV1020

MARTINSRIED, Germany—MediGene AG has announced that the interim analysis of a phase I/II trial of its oncolytic herpes simplex virus NV1020 has shown efficacy for the treatment of liver metastases in patients with colorectal cancer. Therefore, the trial will continue as scheduled, with the maximum dosage of the virus. The agent is delivered to the liver at weekly intervals through the hepatic artery. All patients receiving the maximum dosage demonstrated either disease stabilization or a clear regression of liver metastases, the company said in a press release, adding that some patients showed regressing metastases in other organs as well.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.